
        <!DOCTYPE html>
        <html>
        <head>
            <title>Syndax Pharmaceuticals Inc. (SNDX) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">Syndax Pharmaceuticals Inc. (SNDX)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">← Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">10</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">6</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.32</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=beca5818b57a911096ee584270b649f5d50b074278bcba9bc5cd6ed9c7265372" target="_blank" rel="noopener noreferrer">Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-09</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.77
                                </span>
                            </div>
                            <div class="article-summary">Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts. On June 24, Syndax announced that the US FDA granted Priority Review for its supplement...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=394edc8427b88c43b66e53bc96c892fcb9d7c5920211fa8231ec41e92c3fde67" target="_blank" rel="noopener noreferrer">Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-08</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.32
                                </span>
                            </div>
                            <div class="article-summary">Syndax now has two approved therapies, but the share price remains under pressure despite these milestones. See why SNDX stock is a Buy....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=79f4a6f2c115c79965afa8e74b5e37fa423e32d65aff8d7f8b45d10d4e1ebf1b" target="_blank" rel="noopener noreferrer">Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-02</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9ecfab2bc2253c48f5be6962b915ef74b9a0a4e7252eb9668aa767a2c77f39f8" target="_blank" rel="noopener noreferrer">Syndax Pharmaceuticals, Inc.(NasdaqGS: SNDX) added to Russell 3000E Value Index</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Syndax Pharmaceuticals, Inc. added to Russell 3000E Value Index......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=bdb7ea128b0fa5d7131f87126d72e89a46a90124e026e73f7931a91a90e14608" target="_blank" rel="noopener noreferrer">Syndax Pharmaceuticals, Inc.(NasdaqGS: SNDX) added to Russell 2000 Value Index</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.30
                                </span>
                            </div>
                            <div class="article-summary">Syndax Pharmaceuticals, Inc. added to Russell 2000 Value Index......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=7fd55e246baead7c4b7eded65b32289b257a6729983644f8d7b286cab094c007" target="_blank" rel="noopener noreferrer">Syndax Pharmaceuticals, Inc.(NasdaqGS: SNDX) added to Russell Small Cap Comp Value Index</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.71
                                </span>
                            </div>
                            <div class="article-summary">Syndax Pharmaceuticals, Inc. added to Russell Small Cap Comp Value Index......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=1fe89c1d907d57ce485e23a7dbf3ae3606d13849a4a086a931dfa95389943554" target="_blank" rel="noopener noreferrer">Syndax Pharmaceuticals, Inc.(NasdaqGS: SNDX) added to Russell 2500 Value Index</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Syndax Pharmaceuticals, Inc. added to Russell 2500 Value Index......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e48a4d83948ff33be3709c17ef6afff200809b5ce7ddb8a52f13d19f521bf80c" target="_blank" rel="noopener noreferrer">Syndax Pharmaceuticals, Inc.(NasdaqGS: SNDX) added to Russell 3000 Value Index</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Syndax Pharmaceuticals, Inc. added to Russell 3000 Value Index......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e0df4736753bc5298224aafeddef966b15add619e7cfc7ee45d36035396ce697" target="_blank" rel="noopener noreferrer">Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-24</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.32
                                </span>
                            </div>
                            <div class="article-summary">Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best biotech stocks to invest in now. On June 12, Syndax Pharmaceuticals announced that data from the BEAT AML trial involving revumenib were pu...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d6c06b1f392363325234224875df866507a5fdd91c5a9cc1e9f15a2475697f7f" target="_blank" rel="noopener noreferrer">Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-24</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.74
                                </span>
                            </div>
                            <div class="article-summary">– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AM...</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        